Arcellx surges after promising data from mid-stage cancer therapy trial

Shares of cancer therapy developer Arcellx ACLX.O jump 9.8% to $76.39 premarket

Co announces positive mid-stage trial results for Anito-cel, an experimental cancer therapy for multiple myeloma, a type of blood cancer

Therapy targets blood cancer that has relapsed and/or is not responding to treatment

For 112 Of the 117 patients in the trial, the disease was responsive to the therapy, co says

ACLX is up 1.6% YTD, up to last close